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Purpose: To identify the underlying cause of disease in a large family with North Carolina macular dystrophy (NCMD).
Methods: A large four-generation family (RFS355) with an autosomal dominant form of NCMD was ascertained. Family
members underwent comprehensive visual function evaluations. Blood or saliva from six affected family members and
three unaffected spouses was collected and DNA tested for linkage to the MCDR1 locus on chromosome 6q12. Three
affected family members and two unaffected spouses underwent whole exome sequencing (WES) and subsequently,
custom capture of the linkage region followed by next-generation sequencing (NGS). Standard PCR and dideoxy sequencing were used to further characterize the mutation.
Results: Of the 12 eyes examined in six affected individuals, all but two had Gass grade 3 macular degeneration
features. Large central excavation of the retinal and choroid layers, referred to as a macular caldera, was seen in an ageindependent manner in the grade 3 eyes. The calderas are unique to affected individuals with MCDR1. Genome-wide
linkage mapping and haplotype analysis of markers from the chromosome 6q region were consistent with linkage to the
MCDR1 locus. Whole exome sequencing and custom-capture NGS failed to reveal any rare coding variants segregating
with the phenotype. Analysis of the custom-capture NGS sequencing data for copy number variants uncovered a tandem duplication of approximately 60 kb on chromosome 6q. This region contains two genes, CCNC and PRDM13. The
duplication creates a partial copy of CCNC and a complete copy of PRDM13. The duplication was found in all affected
members of the family and is not present in any unaffected members. The duplication was not seen in 200 ethnically
matched normal chromosomes.
Conclusions: The cause of disease in the original family with MCDR1 and several others has been recently reported
to be dysregulation of the PRDM13 gene, caused by either single base substitutions in a DNase 1 hypersensitive site
upstream of the CCNC and PRDM13 genes or a tandem duplication of the PRDM13 gene. The duplication found in the
RFS355 family is distinct from the previously reported duplication and provides additional support that dysregulation
of PRDM13, not CCNC, is the cause of NCMD mapped to the MCDR1 locus.

Families with North Carolina macular dystrophy were
first identified more than 50 years ago [1]. Families initially
were described with various terms for macular dystrophy
and were linked only when genealogy showed a connection
between them. Because the putative founder effect originated
in North Carolina, the disease was named North Carolina
macular dystrophy (NCMD) [2-4]. The mapping of NCMD
in 1992 to chromosome 6q13-q16, called the MCDR1 locus,
led the way for many more families with NCMD to be identified via linkage analysis [5-8]. Affected members of many of
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these families shared a common haplotype on chromosome
6q supporting the concept of a founder mutation.
NCMD is an autosomal dominant form of non-progressive macular impairment, originating during prenatal
development with varying degrees of affectation or grades
in adulthood [4,9]. Despite extensive studies over numerous
years and by many scientists, no cause of disease has been
found in the genes located in the chromosome 6 linkage
region [10].
Recently, the cause of NCMD was identified using
whole genome sequencing of individuals from two families
mapped to the MCDR1 locus [9]. Sequence analysis identified
a nucleotide substitution at chr6:100,040,906 G>T (hg19) that
was subsequently found in nine families. In addition, a C>T
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substitution at chr6:100,041,040 was found in an additional
family with NCMD. These two nucleotide substitutions are
located in a DNase I hypersensitive site 5′ of two genes, PR/
SET domain-containing zinc finger protein 13 (PRDM13;
Gene ID 59336, OMIM 616741) and cyclin-C protein (CCNC;
Gene ID 892, OMIM 123838). In addition to these two nucleotide substitutions, a third family was found to have a 123 kb
duplication of a region that includes the PRDM13 gene and
the DNase I hypersensitive site. Experiments using induced
pluripotent stem cells (iPSCs) suggested that the disease was
likely due to the dysregulation of PRDM13 [9].
This study describes the clinical characterization and
mutation identification of another NCMD family, RFS355,
which maps to the MCDR1 locus. The tandem duplication
identified in this family is different from that reported by
Small et al., further strengthening the premise that dysregulation of the PRDM13 gene, not the CCNC gene, is the cause of
NCMD (MCDR1) [9].
METHODS
This study adhered to the Declaration of Helsinki and was
approved by the Institutional Review Board at each participating institution. Written informed consent was obtained
from each participant before the examination and genetic
studies were performed.
Clinical characterization: Affected family members (n = 6)
spanning three generations underwent ophthalmic exams that
included visual acuity, retinal imaging, and fundus grading
(Figure 1 and Figure 2)
Visual acuity: Electronic visual acuity (EVA) was measured
with a computerized version of the electronic Early Treatment Diabetic Retinopathy Study (E-ETDRS), which has
been described previously [11]. Briefly, single high-contrast
black letters are randomly displayed on a computer screen
surrounded by crowding bars spaced a letter width around the
letter. At the 3 m test distance, the letters are displayed from
20/800 (1.6 LogMAR) to 20/12 (−0.2 LogMAR).
Retinal imaging: Frequency domain optical coherence tomography (fdOCT) retinal imaging, including line and volume
scans, was performed (Spectralis HRA+OCT, Heidelberg
Engineering, Heidelberg, Germany). The fdOCT measurements included the height, width, and depth of the macular
calderas and the width of the papillomacular area, from the
temporal edge of the disk to the nasal border of the caldera.
Color fundus photography used a 60 degree digital
fundus camera (CF-60UD, Canon, Melville, NY, with
Sonomed Escalon image capture software) to capture macula
and optic nerve images of both eyes from most subjects.
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Three subjects also underwent autofluorescence imaging of
the macula.
Fundus grading: The retinal lesion of each patient was characterized as Gass grade 1, 2, or 3 based on the fundus examination and the color fundus photographs (Table 1) [12,13].
Varying degrees of drusen-like deposits were also noted. The
clinical features of each Gass grade are as follows:
Grade 1: Limited to small (<50 μm) yellow drusen in the
macula with possible mild RPE disturbances. Patients have
visual acuity of 20/30 or better.
Grade 2: Larger elevated confluent yellow drusen with
RPE atrophy and/or disciform scars with pigment clumping.
Patients typically have visual acuity in the range from 20/25
to 20/60, although old disciform scars from choroidal neovascularization may lead to acuity in the 20/100 to 20/400 range.
Grade 3: Large central atrophic excavation of the retina
and choroid referred to as a macular caldera. Patients have
visual acuity in the range from 20/40 to 20/200.
Linkage analysis: DNA was extracted from peripheral blood
and saliva using standard protocols [14]. Peripheral blood was
collected by venipuncture into vacutainer tubes containing
EDTA. Whole blood was stored at room temperature or buffy
coats were stored at -80 °C. DNA was extracted using the
Gentra Puregene Blood Kit (Qiagen, Valencia, CA) and the
manufacture’s protocol with slight modifications as described
previously [14]. Saliva was collected in Oragene DISCOVER
(OGR-500) tubes from DNA Genotek (Ottawa, Canada) and
stored at room temperature until DNA extraction could be
performed. The collection tubes containing saliva were incubated at 50° C and DNA extracted using the manufacture’s
protocol with slight modifications as described previously
[14]. DNAs from six affected individuals and three unaffected spouses were genotyped at the Hussman Institute for
Human Genomics Center for Genome Technology using the
Affymetrix Genome-Wide Human SNP Array 6.0 (Santa
Clara, CA). Processing and analysis were performed as previously described [15]. Briefly, DNA was digested with NspI
and StyI restriction enzymes (New England Biolabs, Ipswich,
MA), ligated to adapters and amplified using adapter-specific
primers. PCR products were fragmented, labeled and loaded
on the SNP 6.0 arrays. Hybridization was performed in a
GeneChip Hybridization Oven (Affymetrix, Santa Clara,
CA). Arrays were washed and stained with streptavidin
phycoerythrin and scanned on a GeneChip Scanner 3000 7G
(Affymetrix).
Single nucleotide polymorphism (SNP) genotype calls
and copy number variation (CNV) analysis was performed
on the raw Affymetrix Genome-Wide Human SNP 6.0 array
1240
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data using Genotyping Console™ (Affymetrix). PLINK was
used for quality control and assessment [16]. Heterozygosity
and inter-SNP distance were used to select a subset of SNPs
for linkage analysis. All chosen SNPs were at least 0.2 cM
apart and had average heterozygosity of 0.5. Centre d’Etude
du Polymorphisme Humain (CEPH) Caucasian (CEU) data
set allele frequencies were used for all calculations [17].
MERLIN was used to perform multipoint linkage analysis
using a dominant model with 90% penetrance in heterozygotes and disease allele frequency of 0.0001 [18,19].

and D6S434. Fluorescently labeled primers for amplifying
the STRs were obtained from Applied Biosystems (Carlsbad,
CA). Genomic DNA from all available family members
was amplified and separated on a 3500xL DNA Sequencer
(Applied Biosystems). STR alleles were determined using
GeneMapper V3.7 (Applied Biosystems).

Additional haplotype analysis was performed using short
tandem repeat (STR) markers D6S1610, D6S300, D6S1671,

Exome capture next-generation sequencing: Exome capture
was performed using a Nimblegen SeqCap EZ Human

Genomic paired-end library construction: Genomic DNA (1
μg) was used to make Illumina paired-end libraries according
to the manufacturer’s protocol (Illumina Inc., San Diego,
CA), with slight modifications as described previously [15].

Figure 1. RFS355 pedigree and duplication typing. A: Pedigree of NCMD family RFS355. Circles indicate female individuals while squares
indicate male individuals. Diagonal lines indicate a deceased individual. Filled symbols indicate affected individuals while unfilled symbols
indicate unaffected individuals. Individual ID numbers are located below the symbols. B: PCR product analysis of the presence or absence
of the 69 kb duplication. PCR products of the three amplimers were combined and separated on an agarose gel. Results from each family
member are in the lane directly underneath their symbol in the pedigree. The presence of the bottom band (shown by the arrow) indicates
these individuals have the duplication on chromosome 6q.
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Figure 2. FdOCT. Each figure represents a b-scan through the macula from either a 9 mm line or volume scan. The scans consist of 100 or
15+ averaged scans taken with autoretinal tracking. The location of each scan is shown in the infrared image (bold green line). A: Grade 1
eye in 9395. B: Grade 2 eye in 8688. C: Grade 3 eyes in 9395, 8602, and 8686, respectively.

Exome Library v2.0 (Roche, Madison, WI) according to the
manufacturer’s protocol. Illumina paired-end sequencing
(2×100 bp), alignment, and variant calling were performed as
described previously [20].
Targeted capture next-generation sequencing:
Custom capture and next-generation sequencing—A
custom library was designed to capture genomic DNA found
in the published MCDR1 locus. This custom library targeted
all non-repetitive coding and non-coding DNA on chromosome 6 from 81,907,766–101,730,611 bp (hg19) [4,7,10,21,22].

Genomic libraries were hybridized with the MCDR1 capture
library according to the manufacturer’s protocol [14]. The
KAPA SYBR FAST qPCR Kit (KAPA Biosystems, Woburn,
MA) was used for library quantification to determine the
amount required to generate 180,000 clusters on a single
lane of the Illumina GAIIx platform. Three lanes of 2×100 bp
paired-end sequence were generated for each patient library
using the SBS Sequencing Kit Ver. Three (Illumina).
Alignment and variant identification—Illumina reads
were mapped to the human reference sequence (GRCh7-lite)
using BWA v0.5.9 with parameters -t 4 -q 5; duplicates were

Table 1. Summarization of physical exams performed.
Pt ID

Age

Sex

Eye

Visual
Acuity

OCT Focus
Diopter

Caldera (Grade 3)
Height Width Depth

Papillo-Caldera
Distance

8603

5

M

OD
OS

20/80
20/50

1.61
1.71

3549
2930

4170
3617

671
398

2784
3137

8687

7

M

OD
OS

20/80
20/63

N/A
0.31

5095
4889

6617
6302

*1191+
*1195+

3087**
3585

8602

39

M

OD
OS

20/63
20/63

0.58
1.07

3990
4309

5028
4987

1098
1222

2170
2041

8686

39

M

OD
OS

20/80
20/63

0.72
0.24

3802
3304

4289
3498

611
379

2292
2612

9395

44

F

OD
OS

20/100
20/16

−0.91
−0.15

3468
Grade 1

3083

669

1968

8688

68

F

OD
OS

20/63
20/125

0.91
1.14

2666
Grade 2

3219

570

2490

See Figure 1 for patient ID’s. N/A-data not available. *The +indicates an approximate measurement as both edges and bottom of caldera
could not be visualized at same time. **Distance measure on fundus color image as no OCT scan was available of the papillo-macular
bundle areas.

1242

Molecular Vision 2016; 22:1239-1247 <http://www.molvis.org/molvis/v22/1239>

marked using Picard v1.46. Reads with a mapping quality
of zero, or that were marked as duplicates by Picard, were
excluded from further analysis.
Putative SNPs and indels were called in the exome data
using VarScan 2 and the following thresholds: coverage ≥8X,
phred base quality ≥15, minimum variant allele frequency
≥10%, and Fisher Exact Test p value <0.05 [23]. False positives were removed from paralogous alignments, local
misalignments, sequencing errors, and other factors by
filtering the SNVs to remove any with strand bias, read position bias, or multiple high-quality mismatches in supporting
reads. Predicted indels were filtered to remove small events
around homopolymers, which likely are false positives.
Copy number analysis—On average, a 181X depth was
achieved for affected individuals and a 185X depth for unaffected individuals across the approximate 19.8 Mbp region
of interest on chromosome 6. To search for copy number
changes, the region of interest was divided into non-overlapping 100-bp segments and average read depth for affected
(n = 3) and unaffected (n = 2) individuals were computed
according to SAMtools (r982) mpileup. The magnitude and
direction of the copy number change were computed as log2
(affected_depth/unaffected_depth). The resulting log2 values
were segmented using the “DNAcopy” package in R with
smoothing (data.type=“logratio,” undo.SD=4).
PCR confirmation and segregation analysis: PCR primers
were designed to span the predicted CNV break points and
the resulting junctions of the normal and duplicated genomic
regions (Figure 3). PCR amplifications were performed using
AmplitaqGold™ 360 Master Mix (Fisher, Waltham, MA) and
the following amplification conditions: 95 °C 5 min; 95 °C
1 min, 56 °C 1 min, 72 °C 1 min x35; 72 °C 5 min; 8 °C
hold. Upon amplification, each PCR product was sequenced
using standard dideoxy fluorescence Sanger sequencing and
a 3500XL Genetic Analyzer (Applied Biosystems). Products
were combined and run on agarose gels to confirm duplication segregation with disease (Figure 1). Primer sequences are
available upon request.
RESULTS
Six affected members of the RFS355 family underwent
comprehensive clinical exams. Clinical data are presented in
Table 1. The six affected individuals were tested at several
different ages spanning the first to sixth decades of life. Each
individual had good to moderate visual acuity ranging from
20/16 to 20/125. Technical details related to the acquisition
of OCT in these patients have been reported previously [24].

© 2016 Molecular Vision

A single eye of individual RFS355–9395 had a grade 1
Gass score while a single eye of RFS355–8688 was grade 2
(Figure 2). All the other eyes had grade 3 Gass phenotypes
with varying size calderas, where the smallest were only half
the size of the largest. Calderas were centered in the macula
at the location of the missing fovea. In spite of the wide range
of sizes, the distances between the disk and the nasal edge of
the caldera were relatively similar, suggesting that the expansion during caldera formation was primarily in the temporal
direction. The preserved nasal retina typically contained the
preferred locus of fixation, which probably explains the good
vision in these patients. The size and depth of the calderas
were not age dependent, as the youngest individual tested
(RFS355–8687) had the largest lesion when compared to
older family members.
Genome-wide linkage analysis was performed on all
available affected and relevant unaffected family members
(n = 9) using Affymetrix Genome-Wide Human SNP Array
6.0 and MERLIN analyses. The majority of the genome had
logarithm (base 10) of odds (LOD) scores of less than −2. A
few genomic regions were also found to have LOD scores
between −2 and 0. Only one region was found to have a
LOD score above zero. This region on chromosome 6 had a
maximum LOD score of 1.8. Chromosome 6q STR markers
confirmed that a consistent haplotype existed in all affected
family individuals and was not present in any unaffected
individuals. The common haplotype was located on chromosome 6q14-16 in a region consistent with the reported North
Carolina macular dystrophy locus, MCDR1 [25].
On the initial examination of the exome data, no potentially deleterious point mutations or small indels within
coding sequences of the genes in the linkage region were
observed to segregate with disease in the family. To increase
coverage and examine any possible copy number variations, a custom capture library was designed to capture as
much of the MCDR1 locus as possible, including the coding
sequences and introns and other non-coding, non-repetitive
DNA sequences.
Analysis of the variants identified in the custom capture
region yielded no new candidates. However, analysis of the
data for the CNVs showed an increased copy number in a
region of chromosome 6 indicating a duplication. In the 68.8
Kbp region of duplication, the read depths were 1.5-fold
higher in the affected individuals (283X for affected, 195X
for unaffected, log2 ratio = 0.563; Figure 4).
When the duplication was detected, there was no
convincing way to determine if or how this duplication was
related to disease. Subsequently, the recent paper by Small
et al. identified a duplication in another family with NCMD
1243
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Figure 3. Pictorial representation of the wild-type and pathogenic duplicated regions on chromosome 6. Green bars indicate the wild-type
region on chromosome 6 while the yellow bars indicate the duplicated region. Red asterisks indicate the DNase I hypersensitivity site. Small
arrows below the chromosome bar pictorials are the three pairs of PCR primers that produce different size products. The PCR product
generated from these primers was used to determine the presence or absence of the deletion and the exact sequence of the duplication in
family members (Figure 1B). Red and blue primers should amplify from the wild-type and duplicated chromosomes. The orange primers
amplify only on the duplicated chromosome. Sequencing of the PCR product resulting from the orange depicted primers determined the
exact duplication break point and the inclusion of 5 bp of exogenous DNA, TCCTG, between the wild-type and duplicated regions. Large
horizontal black arrows with gene names above illustrate the strand and transcriptional direction of each gene. Vertical lines and blocks
represent exons. The duplication found of the CCNC gene is only from exons 1 through 9 making it unlikely that any protein is generated
from the duplicated region. The presence of the entire PRDM13 gene downstream from the DNase hypersensitivity site likely causes a change
in PRDM13 protein levels compared to wild-type levels.
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at approximately the same region as the RFS355 family [9].
Given evidence that CNVs are a cause of NCMD, our data
suggested the duplication identified in RFS355 could be a
likely cause of disease in this family.

RFS355 family. Sequencing of the PCR products determined
the exact break points and the 5 bp of inserted, exogenous
DNA sequence (Figure 1 and Figure 3)

Based on the targeted capture CNV results, the genomic
DNA duplication in the NCMD family is located from
approximately 99,996,220–100,065,140 bp (hg19) on chromosome 6q16.2 (Figure 3). To confirm the duplication and
determine its exact size, two pairs of PCR primers were
designed to flank the wild-type sites; the primers amplify
the complete region in affected and unaffected individuals,
regardless of whether the duplication is present or not. A third
set of PCR primers was designed to flank the 6q telomeric
region of the normal chromosome and the centromeric region
of the duplicated 6q regions (Figure 3). PCR products from
one affected and one unaffected individual were sequenced
to determine the exact duplication locations and their relationship to canonical genomic DNA. These amplifications
showed that the duplication segregated with disease in the

DISCUSSION
We investigated a family with a retinal phenotype similar to
that of other families with NCMD. Linkage analysis in this
family mapped the disease locus to 6q14-16, which contains
the MCDR1 locus. Targeted capture NGS and follow-up PCRbased fluorescent sequencing determined that the cause of
disease in this family lies within the MCDR1 locus region.
The retinal disease in this family is caused by a 68,912 bp
duplication which contains an entire intact PRDM13 gene
copy, a partial CCNC gene copy, and a copy of the DNase I
hypersensitive site located between the 5′ ends of both genes.
The distinct mutation in this family with NCMD further
demonstrates that multiple mutations are responsible for the
NCMD phenotype.

Figure 4. CNV detection of chromosome 6q duplication. Copy number change in the CCNC-PRDM13 regions for affected individuals (n
= 3) relative to unaffected individuals (n = 2), as computed by the log2 ratio of the read depth. Blue points represent the log2 ratio inferred
from the mean depth in 100-bp bins. Red lines indicate the copy number segments inferred by the DNAcopy R package.
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As there is only a partial copy of the CCNC gene, it is
probable that any mRNA generated undergoes nonsensemediated decay and no additional CCNC protein is produced,
regardless of the presence of the extra DNase I hypersensitive
site. The only gene in the duplication that is likely to make
intact mRNA and protein is PRDM13. Further, it is likely that
the duplication of the DNase I hypersensitive region affects
the duplicated PRDM13 gene and may even affect the wildtype PRDM13 gene.

5.

Small KW, Puech B, Mullen L, Yelchits S. North Carolina
macular dystrophy phenotype in France maps to the MCDR1
locus. Mol Vis 1997; 3:1-[PMID: 9238090].

6.

Small KW, Garcia CA, Gallardo G, Udar N, Yelchits S. North
Carolina macular dystrophy (MCDR1) in Texas. Retina
1998; 18:448-52. [PMID: 9801042].

7.

Rabb MF, Mullen L, Yelchits S, Udar N, Small KW. A North
Carolina macular dystrophy phenotype in a Belizean family
maps to the MCDR1 locus. Am J Ophthalmol 1998;
125:502-8. [PMID: 9559736].

PRDM proteins are tissue-specific transcription factors
[26]. Research has shown that in induced pluripotent cells,
PRDM13 mRNA levels decrease as stem cells become
mature neural cells [9]. Recently, it was shown that Prdm13 is
expressed in developing and mature mouse retinal amacrine
cells. Prdm13−/− mouse retinas show a decreased number of
amacrine cells in the inner nuclear layer and are thought to
regulate amacrine subtype specification [27].

8.

Reichel MB, Kelsell RE, Fan J, Gregory CY, Evans K, Moore
AT, Hunt DM, Fitzke FW, Bird AC. Phenotype of a British
North Carolina macular dystrophy family linked to chromosome 6q. Br J Ophthalmol 1998; 82:1162-8. [PMID:
9924305].

9.

Small KW, DeLuca AP, Whitmore SS, Rosenberg T, SilvaGarcia R, Udar N, Puech B, Garcia CA, Rice TA, Fishman
GA, Heon E, Folk JC, Streb LM, Haas CM, Wiley LA,
Scheetz TE, Fingert JH, Mullins RF, Tucker BA, Stone EM.
North Carolina Macular Dystrophy Is Caused by Dysregulation of the Retinal Transcription Factor PRDM13. Ophthalmology 2016; 123:9-18. [PMID: 26507665].

The duplicated copy of the PRDM13 gene and hypersensitive DNase site found in RFS355 might lead to overexpression of PRDM1, which may be the cause of NCMD
symptoms, possibly through amacrine cell regulation in the
neural retina. Results presented here further strengthen the
argument presented by Small et al. that dysregulation of the
PRDM13 gene is the cause of families with NCMD that map
to the MCDR1 locus on chromosome 6q [9].
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